PSCA CAR-T cells with or without radiation for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This Phase 1 study tests a prostate cancer treatment made of PSCA-targeted CAR-T cells, with or without radiation, to help control advanced prostate cancer. It aims to find a safe treatment approach and see how well it works in people whose cancer has PSCA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and able to perform daily activities at a good level (ECOG 0–2 or KPS 70+).
- Have metastatic castration-resistant prostate cancer (cancer that keeps growing despite lowering testosterone).
- Your tumor must test positive for PSCA (the study will use tissue from a biopsy, including saved/archival tissue if available).
- Your cancer must be progressing despite at least one advanced hormone-blocking treatment (like abiraterone or enzalutamide).
- You must be well enough for treatment, with recent blood test limits (neutrophils, platelets, liver and kidney function) and an acceptable heart rhythm (QTc ≤ 480).
- If you have not had CAR-T treatment before, you must meet timing rules for prior chemo and prior radiation, and avoid certain meds like strong ongoing steroid or immune-suppressing medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
This study tests a new type of treatment that uses your own immune cells (engineered to target prostate cancer) combined with a hormone therapy drug. It is for men with advanced prostate cancer that has stopped responding to standard hormone treatments.
This Phase 1 study tests whether lab-made immune cells (CAR-T) that target PSMA can treat prostate cancer that keeps growing despite hormone treatment. It may help people whose disease no longer responds to standard endocrine (hormone-blocking) therapy.
This Phase 1 study tests a type of immune cell treatment (CAR T) made to recognize PSMA, a marker on prostate cancer cells. It’s for advanced prostate cancer and aims to find a safe dose and how well the treatment works.
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight advanced prostate cancer that has stopped responding to hormone treatments. The cells are engineered to recognize and attack cancer cells that have specific markers (PSMA and PSCA) on their surface.
This trial tests a new treatment called ACT#001 CAR-T cells, given as a local injection, for prostate cancer that has stopped responding to hormone therapy. It aims to see if this therapy is safe and can help shrink tumors.
Hear when a new Castration-Resistant Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.